Press Release: Actelion completes first-line share purchase program

Actelion Pharmaceuticals Ltd / Actelion completes first-line share purchase program . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

ALLSCHWIL / BASEL, SWITZERLAND - 22 August 2016 - Actelion (SIX: ATLN) today announced that it completed its first-line share purchase program (initiated on 9 December 2013) on 19 August 2016. During this time, Actelion purchased 10,000,000 of its own shares, which represents 8.31% of the issued shares at the time of the start of the share purchases.

The shares were used for the reactive servicing of existing employee option and share ownership programs.

UPCOMING FINANCIAL UPDATES

-- 9M 2016 Financial Results reporting on 20 October 2016

-- FY 2016 Financial Results reporting on 14 February 2017

###

NOTES TO THE EDITOR

ABOUT ACTELION LTD.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R) ). All trademarks are legally protected.

For further information please contact:

Andrew Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

www.actelion.com

Press Release PDF: http://hugin.info/131801/R/2036343/758566.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#2036343

--- End of Message ---

Actelion Pharmaceuticals Ltd

Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

http://www.actelion.com (END) Dow Jones Newswires

   August 22, 2016 01:00 ET (05:00 GMT)- - 01 00 AM EDT 08-22-16